1-4 of 4
Christiane E. Dobbelstein, MD
Close
Sort by
Journal Articles

Prognostic Impact Of a Newly Defined Structurally Complex Karyotype In Patients With AML and MDS After Allogeneic Stem Cell Transplantation

Christiane E Dobbelstein, MD, Elke Dammann, Eva M Weissinger, MD, Michael Stadler, MD, Matthias Eder, MD, Brigitte Schlegelberger, MD, PhD, Arnold Ganser, MD, Gudrun Gohring, MD
Journal: Blood
Blood (2013) 122 (21): 3362.
https://doi.org/10.1182/blood.V122.21.3362.3362
Published: 2013
Journal Articles

Proteomic Pattern-Based Risk Stratification of Outcome Shows Significant Higher Accuracy Compared to HCT-CI in Patients with AML and MDS,

Christiane E Dobbelstein, MD, Jochen Metzger, Elke Dammann, Uwe Borchert, Stefanie Buchholz, MD, Michael Stadler, MD, Matthias Eder, MD, Juergen Krauter, MD, Arnold Ganser, MD, Eva Mischak-Weissinger, MD
Journal: Blood
Blood (2011) 118 (21): 4128.
https://doi.org/10.1182/blood.V118.21.4128.4128
Published: 2011
Journal Articles

Prospective Validation of a Chronic GvHD-Specific Proteome Pattern (cGvHD-MS14) Post Allogeneic Hematopoietic Stem Cell Transplantation

Eva M. Weissinger, MD, Daniel Wolff, Jochen Metzger, Christiane E Dobbelstein, MD, Stefanie Buchholz, MD, Elke Dammann, Uwe Borchert, Annika Krons, Helmut Diedrich, Michael Stadler, MD, Anne M Dickinson, PhD, Ernst Holler, M.D., Hildegard T. Greinix, MD, Juergen Krauter, MD, Arnold Ganser, MD
Journal: Blood
Blood (2011) 118 (21): 1970.
https://doi.org/10.1182/blood.V118.21.1970.1970
Published: 2011
Journal Articles

Atypical Presentations of EBV Reactivation and EBV-Associated PTLD Post-HSCT: Implication for Routine EBV Surveillance after Allogeneic HSCT?.

Christiane E. Dobbelstein, MD, Haytham M. Kamal, MD, Elke Dammann, Bernd Hertenstein, MD, PhD, Eva M. Weissinger, MD, PhD, Arnold Ganser, MD, PhD.
Journal: Blood
Blood (2005) 106 (11): 5364.
https://doi.org/10.1182/blood.V106.11.5364.5364
Published: 2005